ADVERTISEMENT
Poster
1593970
Healthcare Resource Utilization Following 6 Months of Treatment With Olanzapine/Samidorphan: Real-World Assessment of Patients With Schizophrenia or Bipolar I Disorder
Psych Congress 2023
This work was sponsored by Alkermes, Inc.
BACKGROUND/OBJECTIVE: This study examined the impact of initiating treatment with olanzapine/samidorphan (OLZ/SAM) on healthcare resource utilization (HCRU) among patients with schizophrenia (SZ) or bipolar I disorder (BD-I).
METHODS: This retrospective analysis utilized administrative claims data from April 19, 2021 to December 31, 2022 from Komodo Healthcare Map. Adult patients ≥18 years with SZ or BD-I who had continuous enrollment ≥6 months before (baseline) and after (follow-up) OLZ/SAM initiation were eligible. HCRU outcome comparisons included inpatient (IP) admissions and lengths of stay, emergency department (ED) and outpatient (OP) visits between 6-month baseline and follow-up periods.
RESULTS: Included patients (SZ: Nf855; BD-I: Nf691) had a mean age of ~40 years (percent female: SZ=47%; BD-I=69%). Among both the SZ and BD-I cohorts, all-cause IP admissions and ED visits significantly decreased (IP: P
Sign Up
Psych Congress Network Newsletter
